Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GreeceBack to Greece

Clinical trials in Efkarpia – page 17

680 clinical trials in Efkarpia, Greece. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Efkarpia at a glance
680
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

680 trials in Efkarpia

Open in trial search

Colitis ulcerative+1

Recruiting

Study on Long-term Safety of Vedolizumab and Prednisone in Children with Ulcerative Colitis or Crohn's Disease

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:Prednisone
  • Sponsor:Takeda Development Center Americas Inc.

Small cell lung cancer

Recruiting

Study on Ifinatamab Deruxtecan and Topotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:Daiichi Sankyo Inc.

C3 glomerulopathy

Recruiting

Study on Long-Term Effects of Iptacopan in Patients with C3 Glomerulopathy or Idiopathic Immune-Complex Membranoproliferative Glomerulonephritis

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Vedolizumab, Budesonide, and Prednisone for Children with Moderate to Severe Crohn's Disease

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:Budesonide
  • Sponsor:Takeda Development Center Americas Inc.

Squamous cell carcinoma of lung+2

Recruiting

Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:OSE Immunotherapeutics

Myelofibrosis

Recruiting

Study on Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Navtemadlin
  • Sponsor:Kartos Therapeutics Inc.

Systemic lupus erythematosus

Recruiting

Study on Long-Term Safety of Cenerimod for Adults with Moderate-to-Severe Systemic Lupus Erythematosus

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod
  • Sponsor:Viatris Innovation GmbH

Non-small cell lung cancer

Recruiting

Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Indolent systemic mastocytosis

Recruiting

Study of Elenestinib for Patients with Indolent Systemic Mastocytosis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Sponsor:Blueprint Medicines Corp.

Ependymoma

Recruiting

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years
  • Substances:Cisplatin
  • Sponsor:Centre Leon Berard

Rhabdomyosarcoma

Recruiting

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:The University Of Birmingham

Sickle cell disease+1

Recruiting

Long-term safety study of oral etavopivat tablets in children, adolescents and adults with sickle cell disease or thalassaemia who completed previous etavopivat treatment

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Etavopivat
  • Sponsor:Novo Nordisk A/S

Other cities in Greece

The busiest research cities in the country

All 45 cities in Greece

Clinical research in Efkarpia

What the registry says about research in the country

01 Dermatology Research

Extensive trials focusing on hidradenitis suppurativa and atopic dermatitis, evaluating novel therapeutic approaches and treatment combinations to improve patient outcomes.

  • Chronic skin conditions
  • Inflammatory disorders
  • Autoimmune skin diseases

Multiple studies testing new biological therapies and their long-term safety profiles.

02 Autoimmune Conditions

Research centered on lupus erythematosus and Sjögren's Disease, investigating targeted therapies to manage disease progression and symptoms.

  • Systemic autoimmune diseases
  • Novel immunological treatments
  • Disease activity markers

Studies aim to evaluate new therapeutic agents for better disease control.

03 Metabolic Disorders

Innovative trials examining treatments for Type 2 Diabetes and obesity, with focus on cardiovascular outcomes and weight management.

  • Diabetes management
  • Weight control therapies
  • Cardiovascular risk reduction

Research comparing new therapeutic options against established treatments.

04 Oncology Studies

Advanced research in metastatic breast cancer and colorectal cancer, evaluating targeted therapies and combination treatments.

  • HER2-positive cancers
  • Treatment resistance
  • Combination therapies

Focus on improving progression-free survival in advanced disease stages.

Back to GreeceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.